The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.
April 24th 2024
Heinz-Josef Lenz, MD, FACP, discusses the prognostic and predictive value of HER2 expression levels in select patients with colorectal cancer.
Practical Toxicity Management Awareness With FGFR Inhibitors Improves Real-World Patient Outcomes
January 8th 2024Vivek Subbiah, MD, emphasizes the need for improved guidance on practical toxicity management for various FGFR-altered malignancies, highlights best practices for monitoring and managing the most common on-target toxicities associated with FGFR inhibitors, and discusses the key implications of this review for those utilizing FGFR inhibitors.
Optimal Personalization of Therapy In TNBC Necessitates Consistent Biomarker Identification
January 7th 2024Pooja Advani, MBBS, MD, details the encouraging activity of antibody-drug conjugates in triple-negative breast cancer, the importance of utilizing next-generation sequencing to inform treatment selection after progression on CDK4/6 inhibitors in this disease setting, and more.